Astria Therapeutics, Inc. (ATXS)

Market Cap	704.43M
Revenue (ttm)	706,000
Net Income (ttm)	-124.03M
Shares Out	57.08M
EPS (ttm)	-2.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,319,178
Open	12.41
Previous Close	12.35
Day's Range	12.30 - 12.46
52-Week Range	3.56 - 12.72
Beta	0.08
Analysts	Hold
Price Target	24.33 (+97.16%)
Earnings Date	Nov 12, 2025

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder assoc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS
• Website: https://www.astriatx.com

Analyst Summary

According to 6 analysts, the average rating for ATXS stock is "Hold." The 12-month stock price target is $24.33, which is an increase of 97.16% from the latest price.

Price Target

$24.33

(97.16% upside)

Analyst Consensus: Hold